Health Canada has approved ZURZUVAE (zuranoline), the first medication specifically developed and indicated for moderate to severe postpartum depression. The two-week treatment demonstrated clinical improvement within days in trials and is intended to provide a rapid option for an illness that affects about one in five women in Canada.
Biogen, the drugmaker, says ZURZUVAE restores balance between inhibitory and excitatory brain signals. Trial data reported symptom reductions by day three, larger declines by day 15, and a sustained effect at day 45 compared with placebo.
Clinical evidence and trial results
In pivotal trials patients receiving ZURZUVAE had an average reduction of 17.8 points on the 17-item Hamilton Rating Scale for Depression at day 15, compared with a 13.2-point reduction for placebo. Investigators reported measurable improvements as early as day three, with the largest differences emerging at the end of the two-week course.
The drug is administered as a 14-day oral course. Biogen describes the mechanism as modulation of GABAergic activity to rebalance calming and activating signals in the brain, a pathway implicated in the hormonal and neurobiological changes that can trigger postpartum depression.
Safety profile and breastfeeding considerations
Reported adverse effects in trials included dizziness in 13 per cent of participants, sedation in 10 per cent and sleepiness in 28 per cent. Regulators and clinicians note that long-term safety data are limited.
There isn’t long-term data available, so it is important for patients to be informed early by health professionals about potential side effects to monitor them. Mild and moderate symptoms are manageable, however those experiencing severe levels of sedation and drowsiness might need to stop the treatment and look at traditional solutions.
Dr. Benico Frey, psychiatry and neuroscience professor, McMaster University
Breastfeeding safety remains uncertain. A 2024 clinical study of 14 lactating participants found ZURZUVAE present in breast milk at low levels, about 0.983 per cent. Biogen advises discontinuing breastfeeding while taking the drug because the effects on breastfed infants are unknown.
Access, cost and care pathway implications
Health Canada approval establishes a new pharmaceutical option, but access will depend on provincial coverage decisions and private insurance. Biogen has not announced a Canadian price. In the United States a two-week course has been listed at about US$15,000, a cost that could limit access if private or public payers do not subsidize the medication.
This approval addresses a critical unmet need for Canadian mothers, marking an important step in elevating how we treat what can be a devastating maternal health issue. To any mother experiencing postpartum depression, prompt symptom relief and return to more normal functioning is critical.
Eric Tse, general manager, Biogen Canada
Clinicians warn that ZURZUVAE should not replace efforts to improve access to psychotherapy and community mental health services. The Canadian Institute for Health Information reports one in 10 Canadians wait four or more months for community mental health counselling. Shortages of trained providers for therapies such as cognitive behavioural therapy and interpersonal psychotherapy remain a barrier to non-pharmacological care.
Combined with stigma, these gaps, particularly in therapies preferred by pregnant or breastfeeding patients, make it harder to access care.
Dr. Ryan Van Lieshout, perinatal psychiatrist, McMaster University
Regulatory history and significance
ZURZUVAE was previously approved by the U.S. Food and Drug Administration in August 2023. The United Kingdom and the European Commission granted approvals this past August and September, respectively. Canadian regulators concluded that the benefit-risk profile supports use in moderate to severe postpartum depression, subject to labelled precautions and monitoring.
Experts say the approval fills a pharmacological gap by targeting postpartum depression specifically, a condition often tied to rapid hormonal shifts after childbirth.
A treatment developed specifically for postpartum depression marks an important step forward for maternal mental health. Postpartum depression is often driven by profound hormonal shifts that occur during and after childbirth. Therapy designed to address the impact of these biological changes on mental health addresses a longstanding gap in medical care.
Dr. Crystal Clark, Canada Research Chair in reproductive mental health, University of Toronto
Key facts at a glance
- Indication: moderate to severe postpartum depression
- Treatment course: 14 days, oral ZURZUVAE (zuranoline)
- Onset: improvements reported as early as day three, larger effects by day 15
- Trial efficacy: mean HAM-D17 reduction at day 15 was 17.8 points for ZURZUVAE versus 13.2 points for placebo
- Common side effects: sleepiness (28 per cent), dizziness (13 per cent), sedation (10 per cent)
- Breastfeeding: limited data; Biogen advises discontinuing breastfeeding while taking the drug
- Cost: U.S. list price reported at roughly US$15,000 for a two-week course
Health care providers will need to discuss benefits and risks with patients, including the lack of long-term safety data and current uncertainty about effects during breastfeeding. Provincial coverage decisions and availability of psychotherapy will also shape how widely the medication is used in Canada.
